After trying lots of different cuts of American Wagyu from lots of different producers, I’ve been burned many times — and now I’ve got beef (get it?) with it. I’ve spent a lot of time in Japan, both ...
The Professor reviews the Redodo 200Ah Plus LiFePO4 drop in lead acid replacement battery for rv and off grid living with 2560wh of power and 200 amp BMS. discount codes on solar panels - generators - ...
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with ...
In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard ...
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 ...
MedPage Today on MSN
Frontline targeted therapies plus R-CHOP boosts PFS in high-risk B-cell lymphomas
Add-on tafasitamab and lenalidomide did not negatively impact chemotherapy backbone ...
As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.
Just two weeks after submitting its application for a state tax incentive, Bristol Myers Squibb Co. (NYSE: BMY) has received ...
During the session, Ray told the story of why this patient initially refused treatment and how he convinced her that she was worthy of survival. “When we think about ASCO, we think about science, ...
Bristol Myers Squibb may be leading the way when it comes to pursuing cereblon E3 ligase modulator (CELMoD) drugs, but today, the pharma is standing tall. | Bristol Myers Squibb may have gone big in ...
Bristol Myers Squibb (NYSE: BMY) today announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial ( NCT05552976) of CELMoD (cereblon E3 ligase modulation) mezigdomide in combination ...
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with carfilzomib and dexamethasone (MeziKd ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results